



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT	
MEMBER INFORMATION				
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
PATIENT INSURANCE ID NUI	VIBER:			
MALE FEMALE HEIGHT (IN/CM): WEIGHT (LB/KG): ALLERGIES:				
	IBER, YOU WILL NEED TO SUBMIT A PHI DISCLO			
FOLLOWING LINK: HTTPS://MAGELLANRX.COI	M/MEMBER/EXTERNAL/COMMERCIAL/COMM	ION/DOC/EN-US/PHI DISCLOSURE AUTHORIZA	ATION.PDF	
PATIENT'S AUTHORIZED REPR	RESENTATIVE (IF APPLICABLE):			
AUTHORIZED REPRESENTATIV	VE'S PHONE NUMBER:			
PRESCRIBER INFORMATION				
LAST NAME:		FIRST NAME:		
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:		
STREET ADDRESS:				
CITY:		STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:		
MEDICATION OR MEDICAL	DISPENSING INFORMATION			
MEDICATION NAME:				
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF	QUANTITY:	
		THERAPY/REFILLS:		
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY	'INITIATED:	
DURATION OF THERAPY (SPE	CIFIC DATES):			

Continued on next page







Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST I	NAME:
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
 □ Type II diabetes □ Type II diabetes with established cardiova □ Type II diabetes with diabetic nephropati □ Other DiagnosisICD-10 Co 	ny and albuminuria	
PRIOR AUTHORIZATION.	. PLEASE PROVIDE ALL RELEVANT CLINIC	ALTINFORIVIATION TO SUPPORT A
Please provide documentation. Is the patient's most recent (pre-Invok (HbA1c must be taken within the past No Please provide documentation	filtration rate (GFR) below 30 mL/min/1 cana) HgbA1C obtained in the past 6 mo 6 months if the patient has not been or	nths 7% or greater prior to therapy
Is the patient on dialysis? Yes No Is the patient currently on metformin?		
Did the patient have an inadequate research *Please provide documentation	sponse or intolerance to metform? $\ \square$ Y	'es □ No
(Please Check one) ☐ Estimated glomerular filtration rate ☐ Advanced liver disease with cirrhosi	the following contraindications to metform (GFR) less than or equal to 30 mL/min/is, portal hypertension, ascites, and/or lestablished cardiovascular disease, pleanson	1.73 m2 hepatic encephalopathy
Is the patient's most recent hemoglobic ☐ Yes ☐ No Please provide docume	in A1c level within the past 6 months ecentation.	quals 7.0 - 10.5%, inclusive?
Does patient have symptomatic atherous Please select at least one of the follow History of stroke	-	S □ No

© 2017–2023 by Magellan Rx Management, LLC. All Rights Reserved.

□ History of coronary revascularization procedure

Revision Date: 10.1.2022 CAT0122









Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:
☐ History of peripheral revascularization procedure	
☐ History of amputation secondary to peripheral vascular	disease
☐ Patient is symptomatic with documented hemodynamic	ally-significant carotid or peripheral vascular disease
Is the patient 50 years of age or older AND has 2 or more o	
Please select at least 2 of the following risk factors AND p	rovide chart documentation:
□ Duration of diabetes of 10 years or longer	· · · · · · · · · · · · · · · · · · ·
 □ Systolic blood pressure is greater than 140mmHg while □ Current daily cigarette smoker 	receiving antinypertensive medication
□ Documented albuminuria	
□ Documented discrimination □ Documented HDL-cholesterol equaling less than 39mg/c	li
□ Documented estimated glomerular filtration rate(GFR) is	
bocumented estimated giomerdial intration rate(or k)	above some/minute/1.75m
If for a patient with Type 2 DM with diabetic nephropathy	and albuminuria, please answer the following:
Is patient 30 years or older? ☐ Yes ☐ No	
. ,	
Is the patient's most recent hemoglobin A1c level within the	ne past 6 months equals 6.5 - 12%, inclusive prior to
therapy (HbA1c must be taken within the past 6 months if	the patient has not been on this treatment previously)?
☐ Yes ☐ No <i>Please provide documentation.</i>	
Is the patient's estimated glomerular filtration rate (GFR) e	equal to 30 to less than 90 mL/min/1.73 m2? Yes No
Please provide documentation.	
Is patient currently receiving treatment with an ACE inhibit	tor or an ARB(angiotensin receptor blocker)? Yes No
Please provide documentation.	
Was the patient intolerant of past treatment with ACE inhi	hitors or ARRs? □ Ves □ No
Please provide documentation.	bitors of ARDs: Tes No
rease provide documentation.	
Does patient have nondiabetic renal disease? ☐ Yes ☐ No	
Does patient's renal disease require immunosuppressant,	chronic dialysis or renal transplant? Yes No
	,
Are there any other comments, diagnoses, symptoms, med	lications tried or failed, and/or any other information the
physician feels is important to this review?	
Please note: Not all drugs/diagnosis are covered on all plans	s. This request may be denied unless all required
information is received.	
ATTESTATION: I attest the information provided is true and	·
the Health Plan, insurer, Medical Group or its designees may	•
information necessary to verify the accuracy of the information	tion reported on this form.
Dungguihau Signaturu au Flacturuis I.D. Varification	Data:
Prescriber Signature or Electronic I.D. Verification:	Date:

© 2017–2023 by Magellan Rx Management, LLC. All Rights Reserved. Revision Date: 10.1.2022 CAT0122







Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811

